How to Get a GLP-1 Prescription Online: 4 Steps

Why GLP-1 Receptor Agonists Are Now Prescribed Online

GLP-1 receptor agonists were once confined to endocrinology and obesity medicine offices. Telehealth expansion changed that. The Drug Enforcement Administration's extension of COVID-era flexibilities, combined with Ryan Haight Act modifications debated since 2023, allows licensed prescribers in most U.S. States to prescribe non-controlled medications, including GLP-1 agents, after an asynchronous or synchronous telehealth visit with no prior in-person requirement.

The Science Behind the Medications

GLP-1 (glucagon-like peptide-1) receptor agonists mimic the incretin hormone released from intestinal L-cells after eating. They slow gastric emptying, suppress glucagon secretion, and signal satiety through hypothalamic pathways. The net result is reduced caloric intake and, over months, meaningful fat mass loss.

In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean body weight reduction of 14.9% at 68 weeks compared to 2.4% with placebo (P<0.001). [1] SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg achieved a 20.9% mean weight reduction at 72 weeks, and the 10 mg dose achieved 19.5%. [2]

Which Drugs Are FDA-Approved for Which Indications

Not every GLP-1 agent carries every indication. Knowing the distinction matters because prescribers must document the correct indication.

• Semaglutide 0.5 mg to 2 mg (Ozempic): FDA-approved for type 2 diabetes and cardiovascular risk reduction in adults with established cardiovascular disease. [3]
• Semaglutide 2.4 mg (Wegovy): FDA-approved for chronic weight management in adults with BMI 30+ or BMI 27+ with at least one weight-related comorbidity, and for reducing major adverse cardiovascular events in adults with established cardiovascular disease plus obesity (SELECT trial, N=17,604). [4]
• Tirzepatide 2.5 mg to 15 mg (Mounjaro): FDA-approved for type 2 diabetes. [5]
• Tirzepatide 2.5 mg to 15 mg (Zepbound): FDA-approved for chronic weight management. [6]
• Liraglutide 3 mg (Saxenda): FDA-approved for chronic weight management, though largely superseded by semaglutide given the latter's superior efficacy and weekly rather than daily dosing. [7]

Step 1: Confirm Clinical Eligibility Before You Apply

Most telehealth platforms screen candidates against FDA labeling and the 2023 American Association of Clinical Endocrinology (AACE) Obesity Clinical Practice Guidelines. Confirming you qualify before starting the process saves time and avoids a declined visit.

BMI and Comorbidity Thresholds

The FDA-labeled threshold for Wegovy and Zepbound is a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related condition. Qualifying comorbidities include:

• Type 2 diabetes or prediabetes (fasting glucose 100 to 125 mg/dL, or HbA1c 5.7% to 6.4%)
• Hypertension (systolic BP 130 mmHg or higher, or on antihypertensive medication)
• Dyslipidemia (LDL-C above guideline targets or triglycerides above 150 mg/dL)
• Obstructive sleep apnea (diagnosed by polysomnography or clinical evaluation)

The AACE 2023 guidelines state: "Pharmacotherapy is recommended as an adjunct to lifestyle intervention in patients with obesity (BMI greater than or equal to 30 kg/m²) or overweight (BMI 25 to 29.9 kg/m²) with at least one weight-related comorbidity when lifestyle intervention alone has not achieved or maintained adequate weight loss." [8]

Absolute Contraindications Prescribers Screen For

Telehealth intake forms include contraindication screening. GLP-1 agents carry FDA black box warnings for a risk of thyroid C-cell tumors observed in rodent studies. The following are contraindications to GLP-1 therapy:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity reaction to a GLP-1 agent
• Active or recent pancreatitis (GLP-1 agents are not approved in this setting)
• Pregnancy (category not established; Wegovy and Zepbound should be discontinued at least 2 months before a planned pregnancy per prescribing information)

Active gallbladder disease is a relative contraindication. Rapid weight loss with any agent increases gallstone risk; STEP-1 reported cholecystitis in 0.6% of semaglutide-treated patients versus 0.2% with placebo. [1]

What Labs Are Needed

Many telehealth platforms accept a recent (within 12 months) lipid panel, HbA1c, and basic metabolic panel. Some request a thyroid-stimulating hormone (TSH) result. If you do not have recent labs, several platforms can order them through a national reference laboratory before or concurrent with prescribing.

Step 2: Complete the Telehealth Intake

The intake is the clinical visit. Treat it seriously. Incomplete or inconsistent answers delay the review or result in a declined prescription.

What the Intake Form Covers

A standard intake collects:

1. Current weight and height (for BMI calculation)
2. Past medical history, with specific questions about the contraindications above
3. Current medications (critical for drug-drug interaction screening; for example, GLP-1 agents slow gastric emptying and may affect absorption of oral contraceptives and levothyroxine)
4. Prior weight-loss medication history and outcomes
5. Surgical history, including any prior bariatric procedure
6. Alcohol and tobacco use
7. Cardiovascular history (prior MI, stroke, or heart failure)

Synchronous vs. Asynchronous Visits

State law governs this. In states that permit asynchronous telehealth prescribing for non-controlled substances, a licensed prescriber reviews your intake form and any uploaded documents without a live video call. You receive a decision, often within a few hours. In states that require a synchronous visit, you schedule a video call, typically 15 to 20 minutes.

As of 2025, roughly 35 states permit asynchronous prescribing of non-controlled medications including GLP-1 agents. California, New York, and Texas each have their own telehealth practice standards; a reputable platform will route you to the correct visit type automatically.

Documents to Have Ready

• A government-issued photo ID
• Insurance card (if submitting for coverage)
• Recent lab results if available
• A list of current medications with doses

The HealthRX clinical team uses a proprietary four-domain intake scoring framework that flags candidates needing synchronous review: (1) any contraindication signal, (2) polypharmacy with five or more concurrent medications, (3) HbA1c above 9.0% suggesting poorly controlled diabetes requiring in-person endocrinology coordination, and (4) prior pancreatitis or gallbladder disease history. Candidates with any flag are routed to a synchronous video visit with a board-certified obesity medicine physician rather than the asynchronous pathway.

Step 3: Prescriber Review and Shared Decision-Making

Once intake is submitted, a licensed prescriber, typically a physician, nurse practitioner, or physician assistant with prescribing authority, reviews the full clinical picture and selects the appropriate agent and starting dose.

How the Prescriber Chooses Between Semaglutide and Tirzepatide

Both agents are effective. Prescribers consider several factors when selecting:

Efficacy: Tirzepatide's dual GIP/GLP-1 mechanism produced larger weight loss in head-to-head context. The SUMO trial (N=741, published 2024) compared semaglutide 2.4 mg to tirzepatide 15 mg and reported a mean weight loss of 20.2% with tirzepatide versus 13.7% with semaglutide at 72 weeks (P<0.001). [9]

Tolerability: Nausea is the most common side effect of both agents. In SURMOUNT-1, nausea occurred in 31.0% of tirzepatide 15 mg recipients. [2] In STEP-1, nausea was reported in 44.2% of semaglutide 2.4 mg recipients. [1] GI side effects are almost always dose-dependent and transient, peaking during dose escalation.

Cost and insurance: Insurance coverage varies by payer and indication. Mounjaro and Ozempic have broader diabetes-focused coverage; Wegovy and Zepbound face more frequent prior authorization hurdles for obesity-only indications.

Starting Doses and Escalation Schedules

GLP-1 prescribers use slow dose titration to reduce GI side effects. Standard escalation schedules per FDA prescribing information:

• Semaglutide (Wegovy): Start 0.25 mg once weekly for 4 weeks, then 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then maintenance at 2.4 mg once weekly. Total titration: 16 to 20 weeks.
• Tirzepatide (Zepbound): Start 2.5 mg once weekly for 4 weeks, then increase by 2.5 mg every 4 weeks to a target of 5 mg to 15 mg once weekly. Maximum dose: 15 mg.
• Liraglutide (Saxenda): Start 0.6 mg once daily for 1 week, escalate by 0.6 mg each week to 3.0 mg once daily. Total titration: 4 to 5 weeks.

What Happens If the Prescriber Declines

A declined prescription is not a dead end. The prescriber must document the clinical reason. Common reasons include a contraindication discovered during review, an incomplete intake, or a need for in-person labs first. Most platforms allow you to resubmit after resolving the issue, or to request a synchronous visit for further discussion.

Step 4: Fulfillment, Insurance Navigation, and Ongoing Management

A prescription in hand is not the same as medication in hand. Fulfillment is where many patients hit delays.

Pharmacy Dispensing Options

Retail and specialty pharmacy: Brand-name Wegovy and Zepbound are dispensed through retail pharmacies. Because of prior shortages, many retail pharmacies require an in-stock verification call. Novo Nordisk and Eli Lilly both operate patient assistance programs for eligible uninsured or underinsured patients.

Mail-order pharmacy: Telehealth platforms often partner with mail-order pharmacies that ship refrigerated injectable medications in insulated packaging. Shipping typically takes 2 to 5 business days.

Compounded semaglutide and tirzepatide: During FDA-declared shortage periods, compounded versions of semaglutide and tirzepatide are available from 503A compounding pharmacies and 503B outsourcing facilities. The FDA issued guidance in May 2024 and again in early 2025 confirming that tirzepatide was removed from the shortage list; compounded tirzepatide may no longer be legally dispensed by 503A pharmacies as of March 2025. [10] Compounded semaglutide status should be verified at the time of prescribing, as the FDA's shortage determinations update periodically.

Prior Authorization: What to Expect

Prior authorization (PA) for Wegovy or Zepbound requires documentation of:

• BMI meeting the labeled threshold
• Presence of qualifying comorbidities if BMI is 27 to 29.9
• A documented history of lifestyle intervention (usually 3 to 6 months of diet and exercise counseling)
• In some cases, failure of prior pharmacotherapy (orlistat or phentermine/topiramate)

The PA process adds 3 to 14 business days. Your prescriber's team or the telehealth platform's care coordinator typically handles this submission. If denied, a peer-to-peer review between your prescriber and the insurance medical director resolves a meaningful share of initial denials.

Monthly Follow-Up and Dose Adjustment

The American Gastroenterological Association (AGA) 2022 Clinical Practice Guidelines on obesity pharmacotherapy recommend ongoing monitoring including weight, blood pressure, heart rate, and GI symptom assessment at each dose adjustment visit. [11] Standard telehealth follow-up is monthly during the titration phase, then quarterly once at maintenance dose.

Prescribers assess:

• Weight trajectory (a loss of less than 5% body weight at 12 weeks on the highest tolerated dose is considered inadequate response per FDA labeling for Wegovy)
• GI tolerability and any dose-hold needs
• Any new medications that might interact
• Mental health screening, as GLP-1 agents have been associated with reduced alcohol cravings and suicidality signals under ongoing FDA review as of 2024

The FDA's Adverse Event Reporting System (FAERS) review of suicidality with GLP-1 agents, published in 2024, found no causal signal, though monitoring continues. [12]

Common Barriers and How to Address Them

"My BMI Is 26. Can I Still Qualify?"

Strictly per FDA labeling, a BMI <27 does not meet the labeled threshold for Wegovy or Zepbound. Some prescribers, citing emerging evidence in populations with metabolic disease, prescribe off-label at lower BMIs, but this requires documented clinical justification and is not covered by insurance. A telehealth prescriber operating within standard-of-care guidelines will decline to prescribe at a BMI <27 without a compelling metabolic indication.

"I Have Type 2 Diabetes. Which Agent Is Best?"

For patients with type 2 diabetes and established cardiovascular disease, semaglutide 0.5 mg to 2 mg (Ozempic) has an FDA-approved cardiovascular risk reduction indication based on the SUSTAIN-6 trial (N=3,297), which showed a 26% relative risk reduction in major adverse cardiovascular events versus placebo. [13] Tirzepatide (Mounjaro) provides superior HbA1c reduction in diabetes: SURPASS-2 (N=1,879) showed tirzepatide 15 mg reduced HbA1c by 2.46% versus 1.86% for semaglutide 1 mg (P<0.001). [14]

"I'm Already Taking Metformin or Other Diabetes Medications"

GLP-1 agents are generally safe to combine with metformin and SGLT-2 inhibitors. Combining with sulfonylureas or insulin increases hypoglycemia risk; dose reduction of the sulfonylurea or insulin is typically required. Disclose all diabetes medications during intake.

"I'm Concerned About Muscle Loss During Rapid Weight Loss"

Rapid weight loss with any method includes some lean mass reduction. In STEP-1, approximately 39% of weight lost with semaglutide was lean mass. [1] Prescribers typically recommend resistance training and protein intake of at least 1.2 g/kg of ideal body weight per day during active weight loss. Some protocols add concurrent peptide therapy or creatine supplementation, though evidence for these additions in the GLP-1 context remains limited.

What Reputable Telehealth GLP-1 Platforms Do Differently

Not all online GLP-1 services are equivalent. The FDA and the Federation of State Medical Boards have flagged platforms that issue prescriptions without any clinical review. Signs of a compliant, physician-led platform include:

• A licensed prescriber reviews every intake individually (not an algorithm alone)
• The platform collects and documents a medical history, not just weight and height
• Prescribers are licensed in your state of residence
• A clinical pharmacist reviews for drug interactions before dispensing
• Monthly follow-up is built into the service, not optional

The Federation of State Medical Boards' 2023 telemedicine policy guidelines state: "A physician-patient relationship requires, at minimum, a documented medical history, an evaluation sufficient to establish a diagnosis or identify a condition, and documentation of the clinical basis for any prescription issued." [15]